Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2026)

Amylyx Pharmaceuticals' EBT history runs 6 years deep, the most recent figure standing at -$41.2 million for Q1 2026.

• In Q1 2026, EBT fell 14.77% year-over-year to -$41.2 million; the TTM figure through Mar 2026 stood at -$5.4 million (up 97.53% YoY), while the FY2025 annual figure was -$112000.0, up 99.96% from the prior year.
• EBT was -$41.2 million for Q1 2026 at Amylyx Pharmaceuticals, down from $111.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $111.6 million in Q4 2025 to a low of -$118.6 million in Q1 2024.
• Historically, EBT has averaged -$28.7 million across 5 years, with a median of -$41.2 million in 2026.
• The sharpest annual moves came in 2024 and 2025: EBT slumped 8549.82% in 2024, then soared 395.29% in 2025.
• A 5-year view of EBT shows it stood at -$42.1 million in 2022, then surged by 110.54% to $4.4 million in 2023, then slumped by 951.01% to -$37.8 million in 2024, then jumped by 395.29% to $111.6 million in 2025, then sank by 136.92% to -$41.2 million in 2026.
• The last three EBT figures came in at -$41.2 million (Q1 2026), $111.6 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.